M&A / Deals Lilly, Gilead lead pharma’s M&A boom BioPharma DiveDeal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.Read full story pharminent May 8, 2026 (Last updated: May 10, 2026) BioPharma Dive Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs. Read full story Post navigation Previous: Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapyNext: Next Post Related Stories M&A / Deals Odyssey launches upsized $279M IPO, Seaport docks on Nasdaq pharminent May 8, 2026 M&A / Deals Angelini inks $4.1B Catalyst buy to enter US rare disease market pharminent May 7, 2026 M&A / Deals Roche buys AI-powered diagnostics player PathAI pharminent May 7, 2026
